US Stock MarketDetailed Quotes
CCCC C4 Therapeutics
- 4.550
- +0.360+8.59%
Close Nov 27 16:00 ET
- 4.560
- +0.010+0.22%
Post 20:01 ET
321.18MMarket Cap-2660P/E (TTM)
4.650High4.230Low1.51MVolume4.230Open4.190Pre Close6.84MTurnover3.20%Turnover RatioLossP/E (Static)70.59MShares11.88052wk High1.32P/B215.16MFloat Cap1.06052wk Low--Dividend TTM47.29MShs Float51.210Historical High--Div YieldTTM10.02%Amplitude1.060Historical Low4.523Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
C4 Therapeutics Stock Forum
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors.
The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation sch...
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
MARA - BITCOIN CLIMBING AND ETF APPROVAL AROUND THE CORNER
Artificial Intelligence in Healthcare
Artificial intelligence (AI) hit nearly every sector of the US economy in 2023, with some showing disparate impact over others. However, one long-term area in which AI will have an outsized impact is within healthcare trends. AI’s impact in healthcare sectors should compound at 37% annually, hitting $187.95 billion by 2023 compared to just $15.1 billion las...
No comment yet